Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Vertex Pharmaceuticals is ranked among the best biotech stocks to buy, with 13 billionaires backing the company. Despite ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Sebastien Beauzile from Laurelton, Long Island, has become the first person in New York State to be cured of sickle cell ...

NY resident Sebastien Beauzile was treated with a pioneering new gene therapy approach called Lyfgenia, curing his sickle ...